MARKET

AXSM

AXSM

Axsome Therapeut
NASDAQ
241.67
+4.34
+1.83%
After Hours: 246.64 +4.97 +2.06% 19:11 06/26 EDT
OPEN
239.88
PREV CLOSE
237.33
HIGH
247.50
LOW
238.25
VOLUME
7.35M
TURNOVER
--
52 WEEK HIGH
260.19
52 WEEK LOW
96.09
MARKET CAP
12.44B
P/E (TTM)
-64.6332
1D
5D
1M
3M
1Y
5Y
1D
Axosome Doses First Patient In Phase 3 FOCUS-3 Study For Solriamfetol In Treating ADHD
NASDAQ · 10h ago
Axsome Therapeutics doses first patient in FOCUS-3 trial
TipRanks · 16h ago
Axsome Therapeutics Announces First Patient Dosed In FOCUS-3 Phase 3 Trial Evaluating Solriamfetol As Treatment For Adolescents With Attention Deficit Hyperactivity Disorder
Benzinga · 16h ago
Axsome doses first patient in FOCUS-3 Phase 3 trial of solriamfetol for adolescent ADHD
PUBT · 16h ago
AXSOME THERAPEUTICS INITIATES FOCUS-3 PHASE 3 TRIAL OF SOLRIAMFETOL IN ADOLESCENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Reuters · 16h ago
Weekly Report: what happened at AXSM last week (0615-0619)?
Weekly Report · 4d ago
Axsome Therapeutics Is Maintained at Buy by TD Cowen
Dow Jones · 06/17 14:03
TD Cowen Maintains Buy on Axsome Therapeutics, Raises Price Target to $300
Benzinga · 06/17 13:53
More
About AXSM
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.

Webull offers Axsome Therapeutics Inc stock information, including NASDAQ: AXSM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AXSM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AXSM stock methods without spending real money on the virtual paper trading platform.